25.06.2026
#stocks #macro

Bayer Stock Soars 17% After Supreme Court Win Over Roundup Lawsuits

The U.S. Supreme Court sided with Bayer's Monsanto, blocking thousands of cancer lawsuits over Roundup weedkiller. Shares jumped 17%.

Bayer Stock Soars 17% After Supreme Court Win Over Roundup Lawsuits Image source: MarketWatch

Bayer, the giant German company behind the popular weedkiller Roundup, just got a huge legal victory — and its stock price shot up because of it.

On Thursday, the U.S. Supreme Court (the highest court in America) ruled in favor of Bayer's subsidiary, Monsanto. The decision likely protects the company from tens of thousands of lawsuits claiming that Roundup caused cancer and that customers should have been warned.

Here are the key numbers:

Why did the court side with Bayer? The ruling was 7-2, led by Justice Brett Kavanaugh. The case involved a man named John Durnell, who had won $1.25 million after claiming Roundup gave him non-Hodgkin lymphoma (a type of blood cancer). A Missouri court overturned that verdict.

The court's reasoning was about labels. The U.S. Environmental Protection Agency (EPA — the government body that regulates products affecting health and the environment) decided Roundup is unlikely to cause cancer. Because of this, the company is legally required to use a label *without* a cancer warning. Under federal law, individual states can't force their own different warning labels onto the product.

What this means: The ruling is expected to block current and future lawsuits claiming Roundup causes cancer. This removes a massive financial threat that had been hanging over Bayer for years — which is exactly why investors rushed to buy the stock, pushing the price up sharply.

In short, a big legal win lifted a major cloud of uncertainty, and Bayer's shareholders celebrated.

This is an AI-generated summary. Read the original article at: https://www.marketwatch.com/story/bayers-stock-jumps-after-supreme-court-sides-with-roundup-weedkiller-manufacturer-a747f253?mod=mw_rss_topstories

Disclaimer: This content is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.